The Sting pathway has been identified as an important mechanism by which the innate immune system is capable of recognizing tumors, in order to initiate a type I interferon (IFN-I)-driven inflammatory program that stimulates DC cross-presentation of tumor antigens, ultimately leading to mobilization of tumor-specific CD8+ T cells [28–30]. Here, CD8A is linked to neoplasm.